Client News

Newron provides H1 2022 results and updates on R&D and business activities

Marinomed to attend several upcoming investor and industry conferences

HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery

InflaRx to Present at Upcoming Scientific and Investor Conferences

InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine

AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

Destiny Pharma: Interim results for the six months ended 30 June 2022

iOmx Therapeutics appoints Professor Frances Balkwill to the Scientific Advisory Board

Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

ABIVAX PHASE 2B STUDY RESULTS OF OBEFAZIMOD (ABX464) IN ULCERATIVE COLITIS PUBLISHED IN THE LANCET GASTROENTEROLOGY & HEPATOLOGY